Phase II trial of sorafenib in patients with chemotherapy refractory metastatic esophageal and gastroesophageal (GE) junction cancer

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Janjigian, Yelena Y ^a   Vakiani, Efsevia ^a   Ku, Geoffrey Y ^a   Herrera, Jessica M ^a   Tang, Laura H ^a   Bouvier, Nancy ^a   Viale, Agnès ^a   Socci, Nicholas D ^a   Capanu, Marinela ^a   Berger, Michael ^a   Ilson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ACNE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARID1A GENE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; ESOPHAGUS CANCER; ESOPHAGUS FISTULA; EXOME; FATIGUE; FEMALE; GASTROESOPHAGEAL JUNCTION CANCER; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HAND FOOT SYNDROME; HMGA2 GENE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LETHARGY; MALAISE; MALE; MET GENE; METASTATIC CHEMOTHERAPY REFRACTORY ESOPHAGEAL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEXT GENERATION SEQUENCING; ONCOGENE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PIK3CA GENE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RASH; SKIN TOXICITY; TP53 GENE; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL JUNCTION; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84942877786     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134731     Document Type: Article

References (30)

1. Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513: 202-209. doi: 10.1038/nature13480 PMID: 25079317
2. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, et al. (2009) Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer. PLoS Genet 5: e1000676. doi: 10.1371/journal.pgen.1000676 PMID: 19798449
3. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
4. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 383: 31-39.
5. Qin S, P L A Cancer Center of Nanjing Bayi Hospital, Nanjing, China. Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial.; 2014. J Clin Oncol 32:5s, 2014 (suppl; abstr 4003).
6. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes H-P, et al. (2003) Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. The FASEB Journal.
7. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. (2007) Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels. Cell 131: 463-475. PMID: 17981115
8. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotech 29: 1039-1045.
9. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844. PMID: 17016424
10. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd (2010) Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 28: 2947-2951. doi: 10.1200/JCO.2009.27.7988 PMID: 20458043
11. Chong H, Vikis HG, Guan K-L (2003) Mechanisms of regulating the Raf kinase family. Cellular Signalling 15: 463-469. PMID: 12639709
12. Tew W, Shah M, Schwartz G, Kelsen D, Ilson D (2005) Phase II trial of erlotonib for second-line treatment in advanced esophageal cancer. In: Proc GI ASCO 2005, vol 5 abstr.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute 92: 205-216. PMID: 10655437
14. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31: 4438-4444. doi: 10.1200/JCO.2012.48.5805 PMID: 24190112
15. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. (2006) Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. pp. 4991-4997.
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine 359: 378-390. doi: 10.1056/NEJMoa0708857 PMID: 18650514
17. Connell C, O'Reilly S, Webb G, Moulton B, Parker I, McDermott R, et al. ICORG 06-41: A phase II trial of single-agent sorafenib in the treatment of platinum-pretreated relapsed gastroesophageal adenocarcinoma (GECa). 2014.
18. Martin-Richard M, Gallego R, Pericay C, Foncillas JG, Queralt B, Casado E, et al. (2013) Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study. Investigational New Drugs 31: 1573-1579. PMID: 24077981
19. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338: 221. doi: 10.1126/science.1226344 PMID: 22923433
20. clinicaltrials.gov. Accessed: http://www.cancer.gov/newscenter/newsfromnci/2014/ExceptionalRespondersQandA. The trial number is NCT02243592.
21. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, et al. (2014) Oncogenic and sorafenibsensitive ARAF mutations in lung adenocarcinoma. The Journal of Clinical Investigation 124: 1582-1586. doi: 10.1172/JCI72763 PMID: 24569458
22. Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y, et al. (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet Oncology 15: 1224-1235. doi: 10.1016/S1470-2045(14)70420-6 PMID: 25240821
23. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. (2011) Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Journal of Clinical Oncology 29: 3968-3976. doi: 10.1200/JCO.2011.36.2236 PMID: 21844504
24. Yoon H, Bendell J, Braiteh F, Firdaus I, Philip P, Cohn A, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 4004).
25. Van Cutsem E, de Haas S, Kang Y-K, Ohtsu A, Tebbutt NC, Ming Xu J, et al. (2012) Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial. Journal of Clinical Oncology 30: 2119-2127. doi: 10.1200/JCO.2011.39.9824 PMID: 22565005
26. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet.
27. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6: 327-338. doi: 10.1038/nrclinonc.2009.63 PMID: 19483739
28. Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, et al. (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet 381: 303-312.
29. Demetri GD, Reichardt P, Kang Y-K, Blay J-Y, Rutkowski P, Gelderblom H, et al. (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet 381: 295-302.
30. Pavlakis N, Sjoquist KM, Tsobanis E, Martin AJ, Kang Y-K, Bang Y-J, et al. (2015) LBA-06INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results. Annals of Oncology 26: iv119.